Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
Stephenson Cancer Center
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
New researchers are focused on recurring breast cancer.
OMRF, Stephenson Cancer Center begin tests of experimental compound